Details of Drug-Drug Interaction
| Drug General Information (ID: DDI9EYR5PH) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Cidofovir | Drug Info | Zidovudine | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anti-Hiv Agents | Anti-Hiv Agents | |||||||
| Structure | |||||||||
| Mechanism of Cidofovir-Zidovudine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Decreased metabolism (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Cidofovir | Zidovudine | |||||||
| Mechanism | Inhibit the hepatic metabolism of zidovudine | Zidovudine | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetics | ||||||||
| Factor Description | Alters the metabolism of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Zidovudine therapy should be temporarily discontinued, or the zidovudine dose should be reduced by 50%, on days when cidofovir and probenecid are administered. The usual zidovudine therapy may be resumed on days when the patient is not receiving cidofovir and probenecid. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA. | ||||||||||||||||||